Ilumya — buy and bill, or refer out?
Office-administered and infused products bill under the medical benefit, not the pharmacy benefit. Different form, different queue, different codes — and the first decision is whether the office can carry the drug at all.
Is the office set up for buy and bill?
Carrying the drug means buying it, stocking it and billing it. Most dermatology offices are not set up for it, and the referral path is the normal answer — but it has its own failure mode, which is that a referred start stalls invisibly.
Billing identifiers
1 product populated- 10-digit NDC
- 47335-177-95Ordering from the distributor
- 11-digit NDC
- 47335-0177-95Claim submission — the padded format payers expect
- HCPCS J-code
- J3245How the drug is billed on the medical claim
- HCPCS descriptor and billing unit
- Injection, tildrakizumab-asmn, 1 mgUnits billed must match the descriptor's unit, not the vial
- Place of service
- Physician officePlans restrict where the drug may be given
- Administration CPT
- not in our data — must be sourcedInjection or infusion administration is billed separately from the drug
Verify before you billConfirmed against the binder's own medical-benefit block: 10-digit NDC for ordering 47335-177-95, 11-digit for claim submission 47335-0177-95, HCPCS J3245, descriptor 'Injection, tildrakizumab-asmn, 1 mg', site of service physician office. The administration CPT is still not stated anywhere and is still not to be guessed. Verify every field against the CMS quarterly file before billing.
Answer the question above and the workflow appears here.
Usage events this tool reports
0 events
No events yet.